Interpreting Coagulation Studies for Bleeding Risk

1. The Modern Approach: Moving Beyond Routine Screening

A common misconception is that every patient heading for a procedure needs a PT/INR and PTT to check for bleeding risk. However, modern evidence-based practice has moved away from this "shotgun" approach. For an asymptomatic patient with no personal or family history of bleeding, routine screening labs have a very low yield and are not recommended by major hematology and anesthesiology societies.

The predictive value of a personal and family bleeding history is much higher than that of a routine coagulation test in an unselected patient.

As you just heard, the emphasis has shifted to a more thoughtful, targeted clinical evaluation. Instead of automatic lab testing, the assessment of preoperative bleeding risk is a three-step clinical process:

1. Comprehensive Medication History
2. Structured Bleeding History (personal and family)
3. Focused Physical Examination

Only when this initial screen is positive do we typically proceed with laboratory testing.

This entire workflow is beautifully summarized in a flowchart, which provides a mental model for how to approach any patient before an invasive procedure.

This flowchart illustrates the recommended clinical workflow for assessing preoperative bleeding risk. It starts with medication history, bleeding history, and physical exam, and guides the user on when further evaluation (including lab testing) is required versus when it is not.

2. The Core Components of the Assessment

Let's break down the three pillars of the preoperative bleeding risk assessment.

A. Medication History

A thorough medication history, including over-the-counter drugs and complementary/herbal medicines, is critical. Many agents interfere with hemostasis. Key categories include:

• Anticoagulants: Warfarin, Direct Oral Anticoagulants (DOACs like apixaban, rivaroxaban), Heparins.
• Antiplatelet Agents: Aspirin, Clopidogrel, Ticagrelor.
• NSAIDs: Ibuprofen, Naproxen.
• Complementary Medicines: Garlic, ginseng, ginkgo, and fish oil can all have anticoagulant or antiplatelet effects.

Managing these medications involves balancing the risk of peri-procedural bleeding against the risk of thrombosis if the medication is stopped (e.g., stroke risk in a patient with atrial fibrillation).

B. Bleeding History

A history of abnormal bleeding is the single most important predictor of perioperative bleeding. The goal is to standardize this inquiry. To do this, clinicians often use a Bleeding Assessment Tool (BAT). A BAT is a structured questionnaire that scores bleeding symptoms to quantify a patient's bleeding tendency.

Key questions to ask include:

• Easy bruising or prolonged bleeding from minor cuts?
• Prolonged nosebleeds (>10 minutes) or frequent nosebleeds?
• Heavy menstrual periods?
• Prolonged bleeding after dental extractions?
• Unexpected bleeding after a previous surgery or childbirth?
• Is there a family history of a known bleeding disorder (like von Willebrand disease or hemophilia) or of abnormal bleeding?

A positive answer to these questions warrants further investigation, which may include coagulation studies.

C. Physical Examination

The physical exam looks for signs of an undiagnosed bleeding disorder or a comorbidity that could increase bleeding risk (like liver disease). Key findings to look for include:

• Skin: Petechiae, purpura, ecchymoses (bruises), telangiectasias.
• Signs of Liver Disease: Jaundice, spider angiomata, splenomegaly.
• Joints: Swelling or limited range of motion could suggest hemarthrosis from a congenital coagulopathy.

3. Stratifying the Risk: The Patient, The Labs, and The Procedure

After completing the clinical assessment, you can stratify the patient's risk and decide on the next steps.

When to Order Coagulation Studies

You should now have a clear idea of when to order labs like PT/INR, PTT, and a platelet count. It's not for everyone, but for patients where your initial assessment raises a red flag. Indications for testing include:

• A positive bleeding history (e.g., a high score on a BAT).
• A concerning family history of a bleeding disorder.
• Physical exam findings suggestive of a bleeding diathesis.
• Use of anticoagulant medication (to establish a baseline or ensure the effect has worn off).
• Known comorbidities affecting hemostasis, such as liver disease, renal failure, or hematologic malignancy.

It's important to remember that even when abnormal, lab results must be interpreted in context. For instance, patients with stable cirrhosis often have a prolonged INR because the liver isn't producing clotting factors, but they also have reduced levels of anticoagulant proteins. They exist in a fragile, "re-balanced" hemostasis, and their INR does not linearly predict their bleeding risk.

The Procedure's Inherent Bleeding Risk

The final piece of the puzzle is the procedure itself. A dental cleaning carries a vastly different bleeding risk than open-heart surgery. The International Society on Thrombosis and Haemostasis (ISTH) has developed a practical, three-tiered system to classify procedures. This stratification is crucial for deciding how to manage anticoagulants.

1. Minimal Bleed Risk: Procedures that can often be done without interrupting anticoagulation.
2. Low/Moderate Bleed Risk: Procedures requiring a short interruption of anticoagulation.
3. High Bleed Risk: Procedures requiring a longer interruption and careful management to ensure negligible anticoagulant effect.

Conclusion

You have now learned the comprehensive, evidence-based approach to assessing a patient's bleeding risk before an invasive procedure. This is a core clinical competency that combines history taking, physical exam skills, and the selective, thoughtful use of laboratory tests.

Key Takeaways:

• Preoperative bleeding risk assessment is a clinical process, not just a lab test. It begins with a medication history, a structured bleeding history, and a physical exam.
• Routine coagulation screening (PT/PTT) in asymptomatic patients with a negative history is not recommended.
• Laboratory tests should be ordered selectively based on positive findings from the clinical assessment or the presence of specific comorbidities (e.g., liver disease).
• Overall risk is determined by both patient-specific factors and the procedure's intrinsic bleed risk.
• Procedures are stratified into minimal, low/moderate, or high bleed risk, which guides the perioperative management of antithrombotic medications.

This lesson concludes our module on Coagulation Studies. You have built a strong foundation, from understanding the coagulation cascade and interpreting individual tests to applying this knowledge in complex scenarios like DIC and preoperative risk assessment.

In our next lesson, we will begin a new module, "Inflammatory and Cardiac Markers," starting with the interpretation of C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) in inflammatory conditions.